One of the special features of INNOTHERA, lies in its dual competency: pharmaceutical products and medical textiles. These two areas of expertise complement each other in a harmonious way and work towards the same end, that of treating common daily pathologies, such as venous disease. INNOTHERA’s pharmaceutical laboratory activity enables the Group to apply scientific knowledge and strict pharmaceutical processes to the medical textiles sector, thereby giving it a major advantage over its competitors.
Thanks to its human touch, INNOTHERA can concentrate its efforts on meeting assignments promptly and on achieving an excellent response rate, which is absolutely needed for managing the diversity of profiles and cultures within the group.
Currently, the INNOTHERA Group’s production is 100 % French, with exports amounting to more than 65 % of total sales, and covering more than 100 countries.
This is the price of a disciplined organisation and industrial process perfectly mastered that Innothera products in its French factories more than 20 drugs, controls 15 different dosage forms and distributes medicines in more than 100 countries.
Contact
Web: innothera.fr/en/
As president of the French League Against Cancer, Dr Daniel Nizri highlights the organization’s 106-year legacy of fighting cancer through research funding, health promotion, patient support, and advocacy. He discusses…
After offloading its consumer healthcare division in 2022 and in view of the gradual erosion of its top seller, Somatuline, Ipsen opted to aggressively seek external assets to enrich its…
France is the third most significant clinical research destination in Europe, participating in 50 percent of the trials initiated across the continent. While favourable government policies and unique strengths such…
Hubert Mechin, president of AFCROs, the association that groups clinical research organisations in France, details the organisation’s efforts to help its members stay abreast of changes in the European regulatory…
With revenues projected to reach USD 27.01 billion in 2024, France’s pharma market is ranked fifth globally. Home to a number of well-established local pharma players and a sought-after destination…
Just five months after taking office, Aurélien Rousseau resigned from his role as health minister in protest against France’s recently adopted immigration law. Interim replacement Agnès Firmin Le Bodo, the…
France’s life sciences industry is falling behind its European neighbours, its growth deeply hampered, the French life sciences think tank G5 Santé claims, by abusive paybacks. While the government has…
The latest news from French healthcare and pharma, including an update on the hospital crisis; MaaT Pharma and Skyepharma’s new cGMP microbiome facility; Sanofi’s offloading of central nervous system drugs…
In the French government’s recent cabinet reshuffle, prime minister Elisabeth Borne’s former chief of staff, Aurélien Rousseau was appointed as the new minister of health. Rousseau, having piloted the Île-de-France…
The Contract Development and Manufacturing Organization (CDMO) sector has flousished in recent years as Big Pharma has shifted its attention to its core R&D activities and outsourced other supply chain…
Despite an uncertain macro-economic environment, the French health technology sector continues its growth trajectory, demonstrating both entrepreneurial dynamism and maturity, according to the new edition of the France Biotech study…
The latest news from French pharma, including fears of medicine shortages and suspension of online sales of paracetamol, CARMAT’s artificial heart product entering a study in France, Sanofi’s expanded deal…
See our Cookie Privacy Policy Here
